Holders — by stockHoldings — by fund
Atlas Venture Life Science Advisors, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001917529
$631.2M
disclosed book value
9
positions
50.4%
largest position share
Positions, as of 2026-09-30
top 9 of 9 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | KYMRKymera Therapeutics, Inc. | 2.8M | $318.3M | 50.4% |
| 2 | IRONDisc Medicine, Inc. | 1.4M | $90.6M | 14.4% |
| 3 | OBXObsidian Therapeutics, Inc. | 4.5M | $61.8M | 9.8% |
| 4 | KLRAKailera Therapeutics, Inc. | 5.2M | $59.1M | 9.4% |
| 5 | DYNDyne Therapeutics, Inc. | 3.4M | $55.4M | 8.8% |
| 6 | QTTBQ32 Bio, Inc. | 2.7M | $22.5M | 3.6% |
| 7 | SIONSionna Therapeutics, Inc. | 3.0M | $15.8M | 2.5% |
| 8 | KRROKorro Bio, Inc. | 773,260 | $7.7M | 1.2% |
| 9 | ODTXOdyssey Therapeutics, Inc. | 2,692 | $59,816 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.